The global Spinal Cord Stimulator Market is estimated to be valued at USD 3,011.0 million in 2025 and is projected to reach USD 5,291.4 million by 2035, registering a compound annual growth rate (CAGR ...

For example, in December 2022, Abbott Laboratories introduced the Eterna spinal cord stimulation (SCS) system for managing chronic pain.

Saluda Medical announced that it appointed Barry Regan as its new president and CEO, effective July 14, 2025. Regan most ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to ...

According to a new comprehensive report from The Insight Partners, the electrotherapy systems market is witnessing ...

Avivomed, Inc., a privately held, clinical-stage, medical device company, announced the appointment of Dan Brounstein as its new Chief Executive Officer and Board Member. Brounstein succeeds CEO Steve ...

02.06.2021: Clinical review - Spinal cord stimulation with weak electric current is a neuromodulatory treatment suitable for subgroups of patients with chronic neuropathic pain and certain other pain ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Spinal cord stimulation is an important modality of treatment for some patients with chronic pain. Patient satisfaction following this treatment is comparable to outcomes from spine surgery in Norway.

LONDON, GREATER LONDON, UNITED KINGDOM, June 20, 2025 /EINPresswire.com/ -- Prominently, the neuroplasticity market size has seen significant exponential growth in recent years. In particular, the ...

Boston Scientific’s Neuromodulation segment is charging ahead with a caffeinated jolt of momentum, posting 6.8% operational ...